Google (GOOGL.US)-backed AI drug company Isomorphic Labs launches another funding round: having just raised $2.1 billion five months ago, this round targets a $50 billion valuation.

Zhitong Finance APP has learned that, according to people familiar with the matter, Isomorphic Labs, an AI drug discovery startup spun off from Google DeepMind under Google parent Alphabet (GOOGL.US), is in preliminary talks for a new round of financing, targeting a valuation of at least $40 billion.